Kyongbo Pharmaceutical Co Ltd Total Liabilities
Kyongbo Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Kyongbo Pharmaceutical Co Ltd (214390) has total liabilities worth ₩220.58 Billion KRW (≈ $149.48 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 214390 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kyongbo Pharmaceutical Co Ltd (2014–2025)
Total liabilities of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025. This chart illustrates how Kyongbo Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Kyongbo Pharmaceutical Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Kyongbo Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Kyongbo Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ionic Rare EARTHS Ltd
AU:IXR
|
Australia | AU$2.97 Million |
|
Invictus Energy Ltd
AU:IVZ
|
Australia | AU$1.45 Million |
|
Coloray International Investment Co. Ltd
KQ:900310
|
Korea | ₩40.22 Billion |
|
Les Docks des Pétroles d-Ambès - SA
PA:DPAM
|
France | €22.39 Million |
|
Transaction Capital
JSE:TCP
|
South Africa | ZAC6.01 Billion |
|
Proficient Auto Logistics, Inc. Common Stock
NASDAQ:PAL
|
USA | $163.00 Million |
|
BMT Co. Ltd
KQ:086670
|
Korea | ₩121.36 Billion |
|
Hwa Fong Rubber (Thailand) Public Company Limited
BK:HFT
|
Thailand | ฿385.79 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Kyongbo Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 214390 total asset value.
Liquidity & Leverage Metrics
Kyongbo Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Kyongbo Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kyongbo Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kyongbo Pharmaceutical Co Ltd (2014–2025)
The table below shows the annual total liabilities of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩173.80 Billion ≈ $117.78 Million |
+26.19% |
| 2024-12-31 | ₩137.73 Billion ≈ $93.34 Million |
+12.97% |
| 2023-12-31 | ₩121.92 Billion ≈ $82.63 Million |
+25.90% |
| 2022-12-31 | ₩96.84 Billion ≈ $65.63 Million |
+6.09% |
| 2021-12-31 | ₩91.28 Billion ≈ $61.86 Million |
-6.08% |
| 2020-12-31 | ₩97.18 Billion ≈ $65.86 Million |
+9.62% |
| 2019-12-31 | ₩88.65 Billion ≈ $60.08 Million |
+22.09% |
| 2018-12-31 | ₩72.61 Billion ≈ $49.21 Million |
+14.60% |
| 2017-12-31 | ₩63.36 Billion ≈ $42.94 Million |
-14.76% |
| 2016-12-31 | ₩74.33 Billion ≈ $50.37 Million |
+2.29% |
| 2015-12-31 | ₩72.67 Billion ≈ $49.25 Million |
-27.11% |
| 2014-12-31 | ₩99.70 Billion ≈ $67.57 Million |
-- |
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more